1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione | 847224-03-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione
• 英文别名: 3,4,5,3',4',5'-hexafluorobenzil
• CAS: 847224-03-7
• 化学式: C₁₄H₄F₆O₂
• 分子量: 318.175
• InChiKey: FMFHXBPXDZLEKC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione 、 二苄基甲酮 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.5h， 以84.6%的产率得到3,4-bis(3,4,5-trifluorophenyl)-2,5-diphenylcyclopentadienone
  参考文献：
  名称：

  一种3,4-二(3,4,5-三氟苯基)-2,5-二苯基环戊二 烯酮的制备方法

  摘要：

  本发明公开了一种3,4‑二(3,4,5‑三氟苯基)‑2,5‑二苯基环戊二烯酮的制备方法，以3,4,5‑三氟苯甲醛为起始原料，以维生素B1(VB1)为催化剂，水和乙醇为混合溶剂，在碱性条件下，通过缩合反应制得1,2‑二(3,4,5‑三氟苯基)‑2‑羟基乙酮。再在冰乙酸中，以无水硫酸铜和硝酸铵为共氧化剂，将1,2‑二(3,4,5‑三氟苯基)‑2‑羟基乙酮氧化得到3,4,5‑二三氟苯偶酰。最后在碱性条件下，将3,4,5‑二三氟苯偶酰与二苄基甲酮在热乙醇中反应合成3,4‑二(3,4,5‑三氟苯基)‑2,5‑二苯基环戊二烯酮；本发明的方法反应原料廉价易得，合成步骤简单，反应时间短，反应条件温和，反应过程易于控制，适用于工业化生产。

  公开号：

  CN104151150B
• 作为产物：
  描述：

  2-hydroxy-1,2-bis(3,4,5-trifluorophenyl)ethanone 在 硝酸铵 、 copper(II) sulfate 、 溶剂黄146 作用下， 反应 3.0h， 以78.8%的产率得到1,2-bis(3,4,5-trifluorophenyl)ethane-1,2-dione
  参考文献：
  名称：

  一种3,4-二(3,4,5-三氟苯基)-2,5-二苯基环戊二 烯酮的制备方法

  摘要：

  本发明公开了一种3,4‑二(3,4,5‑三氟苯基)‑2,5‑二苯基环戊二烯酮的制备方法，以3,4,5‑三氟苯甲醛为起始原料，以维生素B1(VB1)为催化剂，水和乙醇为混合溶剂，在碱性条件下，通过缩合反应制得1,2‑二(3,4,5‑三氟苯基)‑2‑羟基乙酮。再在冰乙酸中，以无水硫酸铜和硝酸铵为共氧化剂，将1,2‑二(3,4,5‑三氟苯基)‑2‑羟基乙酮氧化得到3,4,5‑二三氟苯偶酰。最后在碱性条件下，将3,4,5‑二三氟苯偶酰与二苄基甲酮在热乙醇中反应合成3,4‑二(3,4,5‑三氟苯基)‑2,5‑二苯基环戊二烯酮；本发明的方法反应原料廉价易得，合成步骤简单，反应时间短，反应条件温和，反应过程易于控制，适用于工业化生产。

  公开号：

  CN104151150B

文献信息

• Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
  申请人：——

  公开号：US20020119991A1

  公开（公告）日：2002-08-29

  A compound of formula 1 1 wherein: A is a group selected from 2 X − is an anion with a single negative charge; R 1 and R 2 are each independently a C 1 -C 4 -alkyl optionally substituted with hydroxy or halogen; and R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkyloxy, hydroxy, CF 3 , CN, NO 2 , or halogen, with the proviso that at least one of the groups R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is not hydrogen, processes for preparing these compounds, pharmaceutical compositions containing these compounds, and their use as pharmaceutical compositions.

  化合物的化学式为11，其中：A是从2X−中选择的基团，2X−是带有单负电荷的阴离子；R1和R2各自独立地是C1-C4烷基，可选地被羟基或卤素取代；R3、R4、R5、R6、R7和R8各自独立地是氢、C1-C4烷基、C1-C4烷氧基、羟基、CF3、CN、NO2或卤素，但至少有一个基团R3、R4、R5、R6、R7和R8不是氢。本发明还涉及制备这些化合物的方法、含有这些化合物的药物组合物以及它们作为药物组合物的用途。
• Carboxylesterase inhibitors
  申请人：Potter M. Philip

  公开号：US20050054691A1

  公开（公告）日：2005-03-10

  This disclosure relates to amides, aryl sulphonamides, aryl ureas, and α,β-diketones derivatives useful as carboxylesterase esterase inhibitors. The disclosure is also directed to the use of these compounds as selective human intestinal carboxylesterase inhibitors and insect carboxylesterase inhibitors. The disclosure is also directed to pharmaceutical compositions and pesticide formulations containing these compounds, and to methods for treating or ameliorating the toxic effects following administration of drugs such as cancer therapy drugs, treating or ameliorating the effects of a drug overdose, and to the use of the compounds for increasing the effectiveness of insecticides and pesticides.

  本公开涉及可用作羧酸酯酶抑制剂的酰胺类、芳基磺酰胺类、芳基脲类和 α,β-二酮衍生物。本发明还涉及这些化合物作为选择性人体肠道羧酯酶抑制剂和昆虫羧酯酶抑制剂的用途。本发明还涉及含有这些化合物的药物组合物和杀虫剂制剂，以及治疗或改善给药后的毒性效应（如癌症治疗药物）、治疗或改善药物过量效应的方法，以及使用这些化合物提高杀虫剂和杀虫剂效力的方法。
• Structure–activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists
  作者：Vijay K. Gore、Vu V. Ma、Rami Tamir、Narender R. Gavva、James J.S. Treanor、Mark H. Norman

  DOI：10.1016/j.bmcl.2007.08.044

  日期：2007.11

  A novel series of 4,5-biarylimidazoles as TRPV1 antagonists were designed based on the previously reported 4,6-disubstituted benzimidazole series. The analogs were evaluated for their ability to block capsaicin- or acid-induced calcium influx in TRPV1-expressing CHO cells. These studies led to the identification of a highly potent and orally bioavailable TRPV1 antagonist, imidazole 33. (c) 2007 Elsevier Ltd. All rights reserved.
• Identification and Characterization of Novel Benzil (Diphenylethane-1,2-dione) Analogues as Inhibitors of Mammalian Carboxylesterases
  作者：Randy M. Wadkins、Janice L. Hyatt、Xin Wei、Kyoung Jin P. Yoon、Monika Wierdl、Carol C. Edwards、Christopher L. Morton、John C. Obenauer、Komath Damodaran、Paul Beroza、Mary K. Danks、Philip M. Potter

  DOI：10.1021/jm049011j

  日期：2005.4.1

  Carboxylesterases (CE) are ubiquitous enzymes responsible for the metabolism of xenobiotics. Because the structural and amino acid homology among esterases of different classes, the identification of selective inhibitors of these proteins has proved problematic. Using Telik's target-related affinity profiling (TRAP) technology, we have identified a class of compounds based on benzil (1,2-diphenylethane-1,2-dione) that are potent CE inhibitors, with K-i values in the low nanomolar range. Benzil and 30 analogues demonstrated selective inhibition of CEs, with no inhibitory activity toward human acetylcholinesterase or butyrylcholinesterase. Analysis of structurally related compounds indicated that the ethane- 1,2-dione moiety was essential for enzyme inhibition and that potency was dependent on the presence of, and substitution within, the benzene ring. 3D-QSAR analyses of these benzil analogues for three different mammalian CEs demonstrated excellent correlations of observed versus predicted K-i (r(2) > 0.91), with cross-validation coefficients (q(2)) of 0.9. Overall, these results suggest that selective inhibitors of CEs with potential for use in clinical applications can be designed.
• NEUE ANTICHOLINERGIKA, VERFAHREN ZU DEREN HERSTELLUNG UND DEREN VERWENDUNG ALS ARZNEIMITTEL
  申请人：Boehringer Ingelheim Pharma GmbH & Co.KG

  公开号：EP1328524B1

  公开（公告）日：2012-12-12